WHWK ▲ +1.0% - Whitehawk Therapeutics, Inc. $WHWK - Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026 Whitehawk Therapeutics shares rose 1.0% following the company's presentation of real-world analyses at WCLC 2026 demonstrating PTK7 as a durable antibody-drug conjugate target in EGFR wild-type non-small cell lung cancer. The data presentation adds clinical support to the company's PTK7-targeting program in a patient population with limited treatment options. 13-SEP-2026 09:31 PM ET